MoneyTreeTM venture capital funding: Capital crunch

  • Print-friendly version
05/22/2013 by Pharmaceuticals & life science
MoneyTree<sup>TM</sup> venture capital funding: Capital crunch

At a glance

The life sciences share of total venture funding declined from 28% during the last quarter of 2012 to 23% during the first quarter of 2013. Biotechnology, raising $875 million in 96 deals during the first quarter, placed a distant second in dollars raised behind software, which drew $2.3 billion in 329 deals.

The life sciences share of total venture funding declined from 28% during the last quarter of 2012 to 23% during the first quarter of 2013. Biotechnology, raising $875 million in 96 deals during the first quarter, placed a distant second in dollars raised behind software, which drew $2.3 billion in 329 deals.

US venture capital funding for the life sciences sector, which includes biotechnology and medical devices, dropped in value and volume during the first quarter of 2013, according to the MoneyTree™ Report from PricewaterhouseCoopers LLP (PwC) and the National Venture Capital Association (NVCA) based on data provided by Thomson Reuters. VCs invested $1.4 billion in 167 life sciences deals during the quarter, compared with $1.6 billion in 199 deals during the same period of 2012.